key: cord-0027509-f172r4iz
authors: Filep, János G.
title: Clearing NETs with T-series resolvins
date: 2022-02-24
journal: Blood
DOI: 10.1182/blood.2021014936
sha: ace25e1a81ffd88fd00373c936c2892f0b468424
doc_id: 27509
cord_uid: f172r4iz

nan

studies to look for high penetrance for myeloid malignancy predisposition for these genes may be difficult because variants in some of these genes also predispose to breast cancer and a range of solid tumor malignancies. 2 These families may present with heterogeneous pancancer phenotypes, complicating segregation studies. Alternative evidence for risk of myeloid predisposition for some genes or alleles in the DDR pathway could be more amenable to careful casecontrol studies, because, collectively, they are identified more frequently than very rare myeloid predisposition gene mutations, such as in RUNX1, which was not identified as germline in any patients in this study. Understanding the role of DDR pathway mutations in HMs could lead to the extension of specific treatment approaches that are efficacious for this subgroup, such as PARP inhibitors, which, for unselected AML, have limited activity, at least in the single-agent trial setting. 10 This study also highlights 1 of the principal challenges for clinical laboratories today. Of the 1547 variants curated, 252 patients (65%) had $1 variant classified as a variant of uncertain significance (VUS). Attempting to understand whether a VUS is vicious (truly pathogenic), vexing (unable to be resolved), or veiled (truly benign) often requires extensive followup, including de novo/segregation studies or functional studies.

Finally, this study made clear that routine germline genetic profiling of patients with leukemia could overcome some of the deficits of incomplete family history (due to biology [ie, incomplete penetrance] or missing information). Although, overall, their clinical information showed that 15% of individuals had a known family history of HMs, these overlapped, but did not intersect completely, with individuals who had P/LP germline variants in clinically actionable genes. As the field continues to move toward precision medicine in the diverse fields of diagnosis, prognosis, treatment, and monitoring for AML, this study adds to the accumulating evidence that including prospective assessment of the germline genetics in patients is an important consideration. In this issue of Blood, Chiang et al 1 report that the T-series of resolvins (RvTs) reduce the formation of neutrophil extracellular traps (NETs) and enhance NET clearance by macrophages, thereby identifying a novel mechanism for the resolution of infections and coagulopathies.

Neutrophils play a key role in host defense against invading pathogens and are rapidly deployed to sites of infection or injury. However, many of the defense mechanisms they use to destroy microorganisms are potentially deleterious to the host. Among these mechanisms is release of NETs (also known as NETosis), which consist of a nucleic acid scaffold decorated with histones and granular proteins to entrap and kill bacteria, viruses, and fungi. 2 Because the effects of NET components are not restricted to microbes, excessive or uncontrolled NET formation can inflict damage to the surrounding tissue, thus maintaining a pro-inflammatory and pro-thrombotic environment that underlies various pathologies, including autoimmune diseases, 3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coagulopathies, and acute respiratory distress syndrome (ARDS). 4 To ensure timely resolution of acute inflammation, neutrophils need to be disarmed and removed from the affected sites. Resolution of inflammation is an active process governed by specialized pro-resolving lipid mediators (lipoxins, resolvins, protectins, and maresins), proteins (eg, annexin A1), and gaseous mediators (eg, hydrogen sulfite and carbon monoxide), which predominantly act on phagocytes and other immune cells. [5] [6] [7] By analyzing lipid profiles in resolution exudates, the authors previously identified a new series of resolvins that originate from a central intermediate of suicidal NETosis (see figure) . 2 The inhibitory actions were comparable to that of resolvin D2. When tested separately, RvT1, RvT2, and RvT4, but not RvT3, also reduced PMA-stimulated NETosis in whole blood as well as interleukin-1b or leukotriene B 4 (LTB 4 )-evoked NET release from isolated human neutrophils. In these assays, RvT1 was the most potent, and RvT3 was significantly less potent than the other RvTs. RvT1 reduced the amount of both extracellular DNA and DNA-bound myeloperoxidase (MPO), critical components of NET assembly. It is unclear how RvT1 signaled to attenuate breakdown of the nuclear envelope, which is thought to precede liberation of DNA, 2 as well as release of myeloperoxidase from primary granules, which requires activation of the Src kinase Hck. 9 RvT1 reduction of MPO release is consistent with earlier studies that reported reduced MPO and neutrophil elastase release by 15-epi-lipoxin A4 and 17-epi-resolvin D1. 9 Importantly, RvTs given together with Staphyloccus aureus, a well-established stimulus for NETosis in vivo, 2 significantly reduced neutrophil accumulation as well as bacterial titers in dorsal air pouches along with markedly lower amounts of long-string NETs in the exudates, which indicates efficient control of infection.

The main implication of these findings is that by targeting NETosis without blocking phagocytosis, RvTs can ensure rapid resolution and prevent bystander injury to the host. However, additional studies will be necessary to assess the therapeutic window and potential of RvTs given after infection.

How NETs are cleared is incompletely understood. Human macrophages can engulf NETs through endocytosis without inducing cytokine secretion. 2 Conversely, impaired NET clearance by macrophages is associated with sustained inflammation, for example, as reported in ARDS. 10 In line with this understanding, Chiang et al report that human monocyte-derived M0 macrophages have higher capacity to ingest NETs than either the pro-inflammatory M1 or the anti-inflammatory M2 phenotypes. The authors show that RvTs in low nanomolar concentrations enhance the uptake of NETs by M0 macrophages with RvT2 being the most potent, followed in potency by RvT1, RvT2, and RvT4. RvT2 activates the cAMP-PKA-AMPK pathway, which mediates phagocytosis in macrophages by resolvin D2 and maresin 1. 7 Consistent with the findings in human macrophages, RvT2 enhanced NET uptake by peritoneal macrophages in mice, which indicates that this RvT is fully operational in the in vivo setting and underscores the translational potential of RvTs.

Although the authors' data infers the involvement of specific receptors for RvTs, these receptors still need to be identified. Pro-resolving lipids signal through distinct G protein-coupled receptors, sometimes in a cell type-specific manner. For instance, resolvin E1 signals through BLT1 in neutrophils and ChemR23 in macrophages to enhance phagocytosis. 5, 7 Because pharmacologic blockade of the resolvin D2 receptor GPR18 or the LTB 4 receptor BLT1 did not affect the actions of RvTs, and because RvT1 did not antagonize LTB 4 signals via BLT1, it is unlikely that RvTs interacted with these receptors. The differences in the potency of RvTs in attenuating NET release and clearance might indicate involvement of different receptors on neutrophils and macrophages. Future studies might focus on these receptors as well as on the potential interplay of RvTs with other pro-resolving circuits.

Chiang et al unveil a novel mechanism in the context of regulation by specialized pro-resolving mediators of host defense during infection. So far, microbes have been fought with pathogen-specific therapies, antibiotics, or antivirals, depending on the nature of invading pathogens, but the adverse consequences of damage from immune activation have not been addressed This study expands the discoveries made by the Serhan laboratory over the years by identifying the members and functions of the superfamily of specialized pro-resolving lipid mediators. 5, 7 Herein, Chiang et al provide compelling evidence on the multipronged actions of 13-series resolvins, and RvT2 in particular, which partly overlap with those of other pro-resolving lipids but also include suppression of NET formation and facilitation of macrophage clearance of NETs in the context of bacterial and viral infections. These findings have considerable therapeutic potential and broad application for mitigating the deleterious consequences of aberrant NET formation.

Funding support for this article was provided by the Canadian Institutes of Health Research (MOP-102619).

Conflict-of-interest disclosure: The author declares no competing financial interests. n R E F E R E N C E S

Resolvin T-series reduce neutrophil extracellular traps

NETosis: how vital is it?

The role of neutrophils and NETosis in autoimmune and renal diseases

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Resolvins in inflammation: emergence of the proresolving superfamily of mediators

Immune resolution mechanisms in inflammatory arthritis

The atlas of inflammation resolution (AIR)

Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections

15-Epi-LXA 4 and 17-epi-RvD1 restore TLR9-mediated impaired neutrophil phagocytosis and accelerate resolution of lung inflammation